HC Q study #44
See all studies
6/5
Negative
Late treatment study
Horby et al., medRxiv, 7/15/2020, doi:10.1101/2020.07.15.20151852 (press release 6/5) (Preprint)
Effect of Hydroxych loroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
RECOVERY trial reports no significant benefit seen for very late stage very sick patients. Results may be due to the unusually high dosage used [1, 2]. Patients were extremely sick (average of 9 days post symptoms, 60% requiring oxygen and an additional 17% requiring ventilation/ECMO), and unusually high death rate was seen in both arms. 1,561 HC Q patients, 3,155 SOC.
A secondary analysis has found several inconsistencies in the data [3], and found evidence of excess mortaliy within the first few days that could be due to overdose.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.
Submit